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Abstract
Background: Environmental factors-induced dysfunction of esophageal squamous epithelium, including genomic
DNA impairment and apoptosis, play an important role in the pathogenesis of esophageal squamous cell cancer.
DNA damage-induced 45a (GADD45a) has been found promoting DNA repair and removing methylation marker,
Therefore, in this study we will investigate whether GADD45a expression is induced and its mechanism in
esophageal squamous cell cancer.
Methods: Two human esophageal squamous cell lines (ESCC), ECA109 and KYSE510 were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS). Lipofectamine 2000 was used to transfect cells. mRNA
level of GADD45a was measured by reverse transcription-quantitive PCR (RT-qPCR), protein level of GADD45a was
detected by western blot and Immunohistochemistry. Global DNA methylation of tissue sample was measured
using the Methylamp Global DNA Methylation Quantification Ultra kit (Epigentek Group) and promoter methylation
was measured by bisulfite sequencing.
Results: GADD45a mRNA and protein levels were increased significantly in tumor tissue than that in adjacent
normal tissue. Hypomethylation of global genomic DNA and GADD45a promoter were found in ESCC. The cell
sensitivity to Cisplatin DDP was decreased significantly in Eca109 and Kyse510 cells, in which GADD45a expression
was down-regulated by RNA interference (RNAi). In addition, silence of GADD45a expression in ESCC cells inhibited
proliferation and promoted apoptosis.
Conclusion: Overexpression of GADD45a gene is due to DNA hypomethylation in ESCC. GADD45a may be a
protective factor in DDP chemotherapy for esophageal squamous cell carcinoma.
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Background
Esophageal cancer is the eighth most common malig-
nancy and the sixth most common cause of cancer-
related death worldwide [1,2], its prevalence and death
rate are continuously increasing and thus has become a
major health concern[3]. Esophageal squamous cell car-
cinoma (ESCC) is the predominant type of esophageal
cancer, comprising almost 95% of cases. The develop-
ment of ESCC is strongly correlated with a number of
dietary and environmental factors, such as alcohol con-
sumption, smoking, hot food, pungent meal and high
levels of nitrates in the soil and drinking water [4].
These pathogenic factors may destroy esophageal squa-
mous epithelium, thus epithelial cells suffer from DNA
damage and apoptosis [5], which may result in genomic
instability and cell transformation. Although multiple
genetic and epigenetic changes have been reported in
ESCC development and progression [6-15], the precise
molecular mechanisms still remain unclear.
Growth arrest and DNA damage-induced 45a
(GADD45a), a nuclear protein, belongs to the DNA
damage-induced 45 family, has been considered to
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damage agents. GADD45a-null mice generated by gene
targeting exhibits severe genomic instabilities [16]. Most
strikingly, mice lacking the GADD45a gene are suscep-
tible to DNA damage-induced tumors, including carci-
nogenesis induced by ionizing radiation, UV radiation
and dimethylbenzanthracene (DMBA) [17,18]. A recent
study showed that GADD45a has a key role in active
DNA demethylation and its overexpression activates
methylation-silenced reporter plasmids and promotes
global DNA demethylation. [19]
DNA methylation in cancer tissue was first observed
more than two decades ago[20] and may be linked to
carcinogenesis[21].The in-depth investigations of the
relationship between DNA methylation and gene expres-
sion provide very important information for understand-
ing cancer and finding the effective therapy strategy.
Presently, GADD45a expression and promoter methyla-
tion status in ESCC have not been reported. We
hypothesized that epigenetic regulation on GADD45a
may play an important role in ESCC development.
In this study, we first detected GADD45a mRNA
expression by reverse transcription- quantitative poly-
merase chain reaction (RT-qPCR) and DNA methylation
status by bisulfite sequence in 40 primary ESCC tissues
and corresponding normal tissues. We further evaluated
the correlations among GADD45a mRNA, DNA methy-
lation and the tumor clinical pathologic stages. RNAi
was subsequently applied to investigate the role of
GADD45a on cell proliferation and apoptosis in esopha-
geal squamous cancer cell line.
Methods
Samples
Tumor tissue and adjacent normal tissue(confirmed by
hematoxylin and eosin) were obtained from 40 esopha-
geal squamous cell cancer patients(Table 1) who under-
went curative resection at the second Xiang Ya Hospital
(Hunan, China) between June 2010 and January 2011
after informed consent was obtained from all the
patients. None of the patients received chemotherapy
and radiotherapy before surgery. Tissues were fixed in
10% buffered formaldehyde solution for pathological
diagnosis and imunohistochemical staining and frozen
in liquid nitrogen for DNA, RNA and protein isolation.
Cell lines
Two human esophageal squamous cell lines, ECA109
and KYSE510 were obtained from American Type Cul-
ture Collection (ATCC) and Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (German
Collection of Microorganisms and Cell Cultures)
Table 1 Clinical character of ESCC patients
Patient/age/
sex
T/N/M/G Condition of one year after
operation
1/64/M T3/N1b/M0/G1-
G2
alive
2/68/M T3/N0/M0/G1 alive
3/58/M T3/N0/M0/G1 alive
4/61/M T0/N0/M0/G1 alive
5/63/M T1b/N0/M0/G2 alive
6/76/F T2/N0/M0/G3 alive
7/62/M T3/N1a/M0/G1 alive
8/55/M T3/N1a/M0/G2 alive
9/63/M T2/N1a/M0/G2 alive
10/47/M T2/N1a/M0/G1 alive
11/42/M T2/N0/M0/G2 alive
12/55/M T3/N0/M0/G1 alive
13/56/M T1b/N0/M0/G1-
G2
alive
14/56/M T3/N1a/M0/G1 dead
15/73/M T4/N0/M1/G2-
G3
alive
16/61/M T3/N0/M0/G2 alive
17/67/M T2/N0/M0/G2 alive
18/59/M T2/N1a/M0/G2 alive
19/55/M T3/N1b/M0/G2 alive
20/58/M T3/N1a/M0/G2 alive
21/57/M T2/N1a/M0/G2 alive
22/65/M T2/N1a/M0/G2-
G3
metastasis in lymph node of nest
23/54/M T3/N1a/M0/G2 alive
24/56/M T3/N0/M0/G2 alive
25/74/M T2/N1a/M0/G2 metastasis in lymph node of nest
26/51/M T2/N1b/M0/G1 alive
27/52/M T3/N1a/M0/G1 alive
28/60/M T2/N1a/M0/G2 alive
29/47/M T2/N0/M0/G2 alive
30/55/M T3/N1b/M0/G2 alive
31/68/M T3/N0/M0/G2 alive
32/71/M T3/N1a/M0/G2 alive
33/55/M T2/N0/M0/G1 alive
34/69/M T2/N0/M0/G2 alive
35/55/M T2/N1b/M0/G2 alive
36/59/M T2/N1b/M0/G1-
G2
metastasis in liver
37/60/M T2/N0/M0/G2 alive
38/54/M T2/N1a/M0/G2 alive
39/62/M T3/N1b/M0/G2 alive
40/59/M T1b/N0/M0/G1-
G2
alive
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1640 medium (Thermo scientific, Beijing, China) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml of
penicillin sodium, and 100 mg/ml of streptomycin sul-
fate, cultured at 37°C in humidified air containing 5%
carbon dioxide air atmosphere. HEEpiC(Human esopha-
geal epithelial cells) cell line was obtained from San
Diego, US (ScienCell). And they were cultured and pro-
liferated in Epithelila Cell Medium-2 at 37°C in humidi-
fied air containing 5% carbon dioxide air atmosphere.
Real-time reverse transcription-polymerase chain reaction
(RT-PCR)
T o t a lR N Aw a si s o l a t e df r o mt u m o ra n da d j a c e n tn o r -
mal tissue using Trizol reagent according to standard
protocol (Invitrogen, USA). cDNA synthesis was per-
formed using RevertAid™ F i r s tS t r a n dc D N AS y n t h e s i s
Kit (Fermentas, Burlington, Canada) and 1 μgo ft o t a l
input RNA according to the manufacturer’s instructions.
Real-time quantitative PCR was performed using a
Rotor-Gene3000 (Corbett Research, NSW, Australia)
and mRNA levels were quantified using SYBR Premix
Ex TaqTM real-time PCR Kit (TaKaRa Biotech [Dalian]
Co., China). b-actin was also amplified and used as a
loading control. The primers for GADD45a,G A D D 4 5 b,
GADD45g, and b-actin used were shown in Table 2.
Bisulfite genomic sequencing
Bisulfite conversion was performed using the Epitect
Bisulfite kit (Qiagen Germany) according to the manufac-
ture’s protocol. The 484 bp GADD45a promoter frag-
ments were amplified using nested PCR, and then cloned
into a pGEM-T vector (Promega USA). The 5 indepen-
dent clones were then sequenced for each of the amplified
fragments. The primers for GADD45a were as follows:
first round, forward 5’-TGTGGGCTGTGTGGGTGTCA-
GATGG-3’ and reverse 5’-GAGGGTTGGCAGGA-
TAACCCC-3’; the second round, forward 5’-
AAAGTTTTTTATTTTTAATGGTTTTT-3’ and reverse
5’-GGTTAAATTGTTGGAGTAGGTTGAT-3 ‘.
Global DNA methylation detection
Genomic DNA was isolated from tissue of tumor and
normal adjacent using the TIANamp Genomic DNA kit
(Tiangen Biotech). Global methylation levels were mea-
sured using the Methylamp Global DNA Methylation
Quantification Ultra kit (Epigentek Group) according to
the manufacturer’s instruction. In this assay, DNA is
immobilized to wells specifically coated with a specific
DNA affinity substratum. The methylated fraction of
DNA can be recognized with a 5-methylcytosine anti-
body and quantified through an ELISA-like reaction.
Absorbance was measured at 450 nm.
Immunohistochemistry
The paraffin sections were made from the tumor tissue
and adjacent normal tissue of patients. All the paraffin
sections were 4 um thick. Firstly the paraffin sections
were baked at 60°C for 1 h and were dew axed with tur-
pentine Oil and 100%, 95%, 75% and 50% alcohol one
by one. The sections were incubated in 1.2% hydrogen
peroxide for 10 min and rinsed in phosphate balanced
solution(PBS), pH 7.4, for 12 min. The sections were
then blocked for 1 h with normal goat serum. After
incubating with the primary rabbit anti-human antibody
for 1 h at room temperature, the cryostat sections were
washed in PBS and incubated with a secondary anti-rab-
bit biotinylated antibody for 30 min, and subsequently
with the streptavidin-HRP complex for 10 min, rinsed
in PBS. And then the sections were stained with ACE
solution for 10 min. Finally the sections were stained
with haematoxylin. The results were analyzed with Point
rating method. We used the percentage of GADD45a-
positiv stained cells and the intensity of GADD45a
expression by the tumor cells to grade all the samples.
And the multiplication of these two grading scores cal-
culates the immunoreactive score for GADD45a expres-
sion (GADD45a-IRS) in stained tissue (%GADD45a
-positive tumor cells × staining intensity = GADD45a-
IRS).
Western blot analysis
For tumor and adjacent normal tissues were frozen in
liquid nitrogen and powdered with mortar and pestle
and lysed by cell lysis buffer. Samples were transferred
to microcentrifuge tubes, homogenized, and protein pel-
leted by microcentrifugation at 14 000 rpm and 4°C for
15 min. The samples were diluted with 2 × sodium
dodecyl sulfate (SDS) sample buffer and boiled. SDS
samples were resolved by polyacrylamide gel electro-
phoresis and transferred onto polyvinylidene difluoride
membrane. The membranes were incubated with the
primary antibodies and then with horseradish peroxi-
dase-conjugated secondary antibodies. The
Table 2 Primers of genes
Gene primers
GADD45a, PF:5’-GCCTGTGAGTGAGTGCAGAA-3’,
RF: 5’-CCCCACCTTATCCATCCTTT-3’
GADD45b PF:5’-TCGGCCAAGTTGATGAATG-3’:
RF: 5’-CAGAAGGACTGGATGAGCGT-3’
GADD45g PF:5’-CGTCTACGAGTCAGCCAAAG-3’
RP:5’-GCCTGGATCAGCGTAAAAT-3’
b-ACTIN PF:5’GCACCACACCTTCTACAATGAGC’3
RP:5’GGATAGCACAGCCTGGATAGCAAC’3
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Lumiglo Reagent (#7003, CellSignaling Inc.).
Transfections
Control small interfering RNA (siRNA) and siRNA tar-
geting GADD45a were designed and synthesized at Qia-
gen USA. The sequences of the siRNA for GADD45a
were as follows: target sequence 5’-
AACATCCTGCGCGTCAGCAAC-3’, sense strand5’-
CAUCCUGCGCGUCAGCAACTT-3’, Antisense strand:
5’-GUUGCUGACGCGCAGGAUGTT-3’. Lipofectamine
2000 was used to transfect siRNA and negative control
into the two cell lines ECA109 and kyse510.
Total RNA was extracted from esophageal squamous
cell cancer tissue, and GADD45a cDNA was amplified
by RT-PCR. The PCR product was doubly digested by
Xbal and Sall, and then recombined into eukaryotic
expression vector. Then, pIRES-GFP-GADD45a was
obtained by G418 selection, and then pIRES-GFP-
GADD45a and pIRES-GFP were transfected into human
esophageal squamous epithelial cells with lipidosome-
packaged method. Meanwhile, the transfected cells were
selected by G418, and then stable transfected cell lines
were obtained.
Drug sensitivity assay
Cells (1 × 10
5/ml) were cultured in 96 cell plates after 1
day of transfectioin. After 1 day of culturing, the cells
were treated with various concentrations of cisplatin
(DDP). After 24 h, 48 h and 72 h of treatment, 20 ul
MTT (Roche, Mannheim Germany) solution (2 mg/ml)
was added to each well, and the plate was then incu-
bated at 37°C for 4 h. Absorbance in individual wells
was determined at 570 nm using a micro plate reader
(Model 450, Bio-rad, CA). Three independent experi-
ments were carried out for each treatment.
Flow cytometric analysis
Eca109 and Kyse510 (4 × 10
5) were seed in 12-well
plates and then were transfected. Transfected Cells were
harvested at 24 h, 48 h, and 72 h for flow cytometric
analysis. Cells were washed twice with PBS and then
incubated with 20 ug/ml PI, 100 ug/ml RNase, and 0.1%
triton X-100 in PBS for 30 min in the dark. The PI
stained cells were analyzed for cell cycle distribution
and apoptosis by using a FACScalibur instrument (BD
bioscience, San Jose, A) equipped with Cell Quest soft-
ware (Becton Dickinson).
Statistical analysis
Students’s t-test for equality of means was used to com-
pare values. Person’s correlation coefficient was used to
determine the relationship. P values less than 0.05 were
considered significant. All analyses were performed with
SPSS version 16.0 software.
Results
Overexpression of GADD45a in tumor tissue of ESCC
The mRNA expression levels of GADD45a, GADD45b,
GADD45g in tumor tissue and adjacent normal tissue
from ESCC were detected. GADD45a mRNA level was
higher in tumor tissue than in adjacent normal tissue (P
= 0.001) (Figure 1A and Table 3). No significant differ-
ence was found in GADD45b( F i g u r e1 Ba n dT a b l e3 )
and GADD45g(Figure 1C and Table 3)mRNA levels
between tumor and adjacent normal tissue. The overex-
pression of GADD45a in tumor tissue of ESCC was
confirmed at the protein level using immunohistochem-
istry (Figure 1E,F and 1G) and western blotting (Figure
1H). GADD45a-positive staining was mainly located in
nucleolus of tumor cells with few positive staining in
surrounding matrix. To show the statistical discrimina-
tion clearly, samples with nuclear GADD45a-IRS < 5
were classified as GADD45a -negative (Figure 1F), and
those with GADD45a-IRS > 5 were classified as
GADD45a positive (Figure 1E), the ratio of GADD45a
positive was higher in tumor tissues than normal tissues
(Table 4).
The correlation between GADD45a mRNA and clinical
pathological stages
We evaluated the correlation between GADD45a
mRNA expressions in the ESCC tissues with clinical
pathological stages. We found that the relative
GADD45a mRNA level was 1.8672 ± 1.26732 in ESCC
tissues from clinical stages I. Moreover, in tissues from
stages II, III and IV, the relative GADD45a mRNA levels
were 4.0800 ± 1.30220,4.4936 ± 1.25856 and 4.3292 ±
2.69446 respectively. (Table 5 and Figure 1D). The pre-
sence of lymph node metastasis, and poor differentiation
were associated with mRNA expression levels of
GADD45a in ESCC (P = 0.007, P =0 . 0 0 6 ,P = 0.010
and P = 0.005, respectively Table 6).
Hypomethylation in promoter of GADD45a in ESCC
We detected the methylation status of CG pairs in 181
bp (position-190 to -165) of GADD45a gene. Amplified
fragments were cloned and five clones were sequenced
for each amplification product from each subject. Figure
2 A and B show the average methylation of each 11 CG
pairs within the promoter region. The mean methylation
status of most CG pairs was decreased in the tumor
group; there were statistically significant difference in
the overall combined mean methylation status between
two groups (0.0545 ± 0.03067 vs 0.0255 ± 0.01788, P =
0.000). (Figure 2C).
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with clinical pathological stages
We compared the level of global DNA methylation in
tumor with normal adjacent tissue. And it was found that
the global DNA methylation level was significantly lower
in tumor than normal adjacent tissue (Figure 2D). By eval-
uating the correlation between global DNA methylation
level in the ESCC tissues and clinical pathological stages.
We found global DNA methylation levels were higher in
stages I and II than that in III and IV stages. And the same
correlation was found between global DNA methylation
and lymph node metastasis. A significant correlation
between global DNA methylation level and clinical patho-
logical stages was observed (P < 0.05) (Table 7).
GADD45a-siRNA transfection decreased the expression of
GADD45a mRNA and protein
The levels of GADD45a mRNA and protein were
detected at 48 h after transfection by RT-qPCR and
western blot. The levels of GADD45a mRNA and
Figure 1 Growth arrest and DNA damage-induced 45a (GADD45a), GADD45b, GADD45g gene expression in tumor tissue compared
with adjacent normal tissue from the same esophageal squamous cancer patients. A, B and C, Relative expression of GADD45a, GADD45b,
GADD45g mRNA in tumor tissues from ESCC patients was measured by quantitative real-time PCR. Results were normalized to the level of b-
actin (loading control). D shows the different expression levels of GADD45a in various TNM stages. G. Protein levels of GADD45a in tumor tissue
and adjacent normal tissue from ESCC patients were assessed by immunohistochemistry. E shows the representative GADD45a-positive staining
in tumor tissue from ESCC patients. GADD45a protein is mainly located in nucleolus of tumor cells. F. Negative control with less GADD45a
staining in normal tissue. H Protein levels of GADD45a in tumor tissue and adjacent normal tissue from ESCC patients were assessed by western
blotting.
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knocking-down group (Figure 3A,B,C).
Depletion of GADD45a in ESCC cells inhibited
proliferation and promoted apoptosis
We observed the proliferation and apoptosis of Eca109
and Kyse510 at 24 h, 48 h and 72 h after transfection.
And we found that cell proliferation of ESCC cells with
GADD45a-siRNA were decreased (Figure 4A and B and
Table 8) significantly. In contrast, the percentage of
apoptosis cells was increased in ESCC cells with
GADD45a-siRNA than negative control (Figure 4C and
4D and Table 9).
Decreased GADD45a expression by gene silence down
regulated the sensitivity of Eca109 and Kyse510 cells to
DDP
We detected the sensitivity of Eca109 and Kyse510 cells
transfected with GADD45a-siRNA to Cisplatin (DDP)
at 24 h, 48 h and 72 h after treatment with DDP, at dif-
ferent concentration (0.5 ug/ml and 1 ug/ml)[22]. As
shown in Figure 5, we observed a decreased sensitivity
of Eca109 and Kyse510 cells to DDP dependent of time
and dose of GADD45a-siRNA transfection in the group
with knock-down GADD45a (Figure 5A,B,C,D).
The relation of GADD45a and global DNA methylation
The level of global DNA methylation was detected in
the group of GADD45a-siRNA and NC-siRNA respec-
tively. Then the result was that GADD45a-siRNA trans-
fection increased global DNA methylation (Figure 6A
and 6B).By making GADD45a overexpressed in normal
human esophageal epithelial cells, it was found that the
overexpression of GADD45a decreased global DNA
methylation (Figure 6C).
Conclusions
Overexpresssion and promoter hypomethylation of
GADD45a gene and global DNA hypomethylation were
found in ESCC tissues, which provide evidence that pro-
moter hypomethylation may be the major mechanism
for activating GADD45a gene in ESCC. The function of
GADD45a in cell proliferation and apoptosis further
demonstrated that overexpression of GADD45a contri-
butes to the development of ESCC.
Discussion
GADD45a, a nuclear protein, is implicated in the main-
tenance of genomic stability probably by controlling cell
cycle G2-M checkpoint [18,23], induction of cell death
[24], and DNA repair process [25-27]. It has been docu-
mented that GADD45a promotes gene activation by
repair-mediated DNA demethylation[19]. As DNA
repair gene, GADD45a is involved in the pathogenesis
of many kinds of human cancers [28]. Recently, Zhang
et al. reported that GADD45a play an essential role in
gene-specific active DNA demethylation during adult
stem cell differentiation [29]. But there is no report
about expression and DNA methylation status of
GADD45a gene and its role in ESCC. In this study,
increased GADD45a expression was observed in eso-
phageal squamous cancer tissues, and overexpression of
GADD45a gene was associated with lymph node metas-
tasis, and poor differentiation and TNM staging of
ESCC. Hypomethylation in promoter of GADD45a and
global DNA hypomethylation in tumor tissues of ESCC
was also identified.
Table 5 Correlation between the expression level of
GADD45a mRNA and pTNM staging
TNM stage Relative GADD45a mRNA P value
I 1.8672 ± 1.26732 0.026
a 0.031
b 0.029
c
II 4.0800 ± 1.30220 0.082
d 0.091
e
III 4.4936 ± 1.25856 0.90
f
IV 4.3292 ± 2.69446
a was the result of compare between stage I and II.
b was the result of
compare between stage Iand III.
c was the result of compare between stage
Iand IV.
d was the result of compare between stage IIand III.
e was the result
of compare between stage II and IV. f was the result of compare between
stage III and IV
Table 6 Correlation between the expression level of
GADD45a mRNA and clinic pathological factors
Total Relative GADD45a mRNA P
Depth of invasion
T1/2 23 2.1683 ± 1.06534 0.007
T3/4 17 4.0265 ± 1.20145
Lymph node metastasis
N0 18 1.5682 ± 0.76238 0.006 a
N1 14 3.8326 ± 1.25123 0.010 b
N2/N3 8 4.8352 ± 1.81245. 0.005 c
a was the result of compare between N0 and N1.
b was the result of compare
betweenN1 and N2/N3
c was the result of compare between stage N0 and N2/N3
Table 3 Relative mRNA level
Gene tumor normal tissue P value
GADD45a 3.4315 ± 1.2301 1.3524 ± 0.7102 0.001
GADD45b 3.2564 ± 1.5201 2.3472 ± 1.0526 0.056
GADD45g 2.9562 ± 1.3458 2.0561 ± 1.0210 0.062
Table 4 The result of immunohistochemistry
Tissue GADD45a-IRS > 5 GADD45a-IRS < 5
Tumor 18/20 2/20
Normal 0/20 20/20
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higher in tumor tissue than in adjacent normal tissue,
which may be due to DNA damage in epithelial cells
induced by injury of esophageal squamous epithelium.
When DNA damage takes place, GADD45a may act as
a player in nucleotide excision repair [25,30]. Reinhardt,
H. C et al. [31]found that following DNA damage, the
p38/MK2 complex delocalized from nucleus to cyto-
plasm to stabilize GADD45a mRNA and MK2 phos-
phorylated PARN, blocking GADD45a mRNA
degradation. Most DNA damaging agents and growth
arrest signals (designated as non-IR treatments) have
been found to induce GADD45a in cells regardless of
p53 status [30]. GADD45a induction following DNA
Figure 2 A and B show the mean methylation status of each CG pairs in the promoter region upstream of GADD45a gene in tumor
tissue and adjacent normal tissue. Compared with adjacent normal tissue, the promoter region with 11 CG pairs (-158,-146,-135,-122,-116,-
110,-104,-96,-91,-84, and-64 bp) upstream of GADD45a gene were hypomethylation in tumor tissue. C, the average methylation levels of CpG
pairs in the region (-190 to-10 bp) of GADD45a promoter is significantly decreased in tumor tissue compared to the adjacent normal tissue. D
shows the global DNA methylation levels of tumor and adjacent normal tissue. Compared with adjacent normal tissue, the global DNA
methylation level in tumor tissue is lower.
Table 7 Correlation between the relative global DNA
methylation and clinic pathological factors
Total Relative global DNA methylation P
Depth of invasion
T1/2 23 0.5612 ± 0.0238 0.017
T3/4 17 0.2535 ± 0.0176
Lymph node metastasis
N0 18 0.5852 ± 0.0185. 0.026 a
N1 14 0.3536 ± 0.0152 0.018 b
N2/N3 8 0.1568 ± 0.0123 0.006 c
a was the result of compare between N0 and N1.
b was the result of compare
betweenN1 and N2/N3
c was the result of compare between stage N0 and N2/N3
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GADD45a induction by certain DNA damage-agents
has been detected in a variety of mammalian cells. For
example, rapid induction of GADD45a after MMS and
UV treatments has been observed in every cell type
tested to date. These cells include multiple mouse cell
lines, human fibroblast, human lymphoblast and multi-
ple human tumor lines [33,34]. Above all, GADD45a
participated in DNA damage repair process; in return,
DNA damage induced its overexpression.
DNA methylation is a major epigenetic mechanism for
gene silencing and genome stability in many organisms
[1,35,36]. In order to investigate the role of GADD45a
in activating DNA demethylation, we explored the
global DNA methylation condition and found global
DNA hypomethylation in tumor tissues of ESCC. This
finding was consistent with the published studies
demonstrating incresed global DNA demethylation
through GADD45a overexpression and DNA hyper-
methylation by scilencing GADD45a gene.[19]. Global
DNA hypomethylation is considered as a feature of
tumorigenic cells [37-39]; it can cause chromosomal
instability, reactivation of transposable elements, and
loss of imprinting [37,38,40]. In the experiment, we also
found promoter hypomethylation of GADD45a in
tumor tissues. Promoter hypomethylation has been
hypothesized to lead to carcinogenesis by encouraging
genomic instability [41]as well as by aberrant activation
Figure 3 mRNA and protein levels of GADD45a were detected by real-time PCR and western blot in ECA109 and KYSE510 with siRNA-
GADD45a transfection. A,B and C show mRNA and protein expression was inhibited significantly in ECA109 and KYSE510 transfected with
siRNA-GADD45a compared with negative control.
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participate in the development of ESCC.
We next investigated the biological effect of
GADD45a in Eca109 and Kyse510 cell lines, and found
that depletion of GADD45a by RNAi inhibited cell pro-
liferation and promoted apoptosis. GADD45a play a
role in the control of the cell cycle G2-M checkpoint.
Takekawa et al. have reported that GADD45a interacts
with MEKK4/MTK1 and activates the JNK/p38 signaling
pathway that induces apoptosis and introduction of the
GADD45a expression vector into tumor cells via transi-
ent transfection induces apoptosis [43]. GADD45a-
mediated JNK/p38 activation is required for BRCA1-
induced apoptosis [44] and UVB radiation-induced
apoptosis is deficient in GADD45a-/- mouse epidermis
[17]. In this study, our results showed that depletion of
Figure 4 A and B show that the ability of cell proliferation in GADD45a-siRNA group was decreased compared with NC-siRNA cells
group. C and D show the percentage of apoptotic cells in GADD45a-siRNA group and NC-siRNA group. Results confirmed that cells of
apoptosis were increased significantly in the group of siRNA -GADD45a than in the group of NC-siRNA.
Table 8 The ratio of cells in S period
GADD45s-siRNA NC-siRNA
24 h 48 h 72 h 24 h 48 h 72 h
Eca109 47.84 ± 14.30 32.25 ± 11.27 25.00 ± 12.01 51.11 ± 16.00 42.50 ± 14.00 31.05 ± 13.25
Kyse510 36.63 ± 8.04 30.00 ± 13.32 20.00 ± 6.00 47.90 ± 15.34 43.50 ± 2.94 26.00 ± 6.12
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and promoted apoptosis, which suggested that
GADD45a may be a novel and effective target for ESCC
therapy.
Cisplatin (DDP) is the frequently-used chemothera-
peutic agent shown to improve survival in patients with
ESCC, as established by randomized controlled trials
and therefore approved by the Food and Drug Adminis-
tration for this use [45-48]. Resistance to chemotherapy,
especially to DDP, has presented itself as a major obsta-
cle in treatment of advanced ESCC. Many reports
demonstrates that disruption of the apoptotic pathway
seems to be a major mechanism of uncontrolled cell
proliferation as well as resistance to chemotherapeutic
Table 9 The percent of cell in apoptosis
GADD45s-siRNA NC-siRNA
24 h 48 h 72 h 24 h 48 h 72 h
Eca109 27.33 ± 12.11 19.00 ± 2.49 9.00 ± 2.10 20.50 ± 8.83 13.41 ± 7.81 7.00 ± 4.01
Kyse510 36.63 ± 8.04 30.00 ± 13.32 20.00 ± 6.00 47.90 ± 15.34 43.50 ± 2.94 26.00 ± 6.12
Figure 5 A and B show the drug sensitivity of ECA109 and KYSE510 after transfection with siRNA-GADD45a. ECA109 and KYSE510 cells
in NC-siRNA group were more sensitive to DDP than that in two GADD45a-siRNA groups at 24 h, 48 h and 72 h with DDP treatment.
Moreover, the percent of survival cells was measured by MTT value. C and D, show that the percent of survival cells at 24 h, 48 h and 72 h with
DDP treatment were degraded in two GADD45a-siRNA groups compared to NC-siRNA groups.
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Page 10 of 13agents[49]. Our finding showed that Eca109 and
Kyse510 cells with knock-down GADD45a have
decreased chemotherapeutic sensitivity to DDP, suggest-
ing GADD45a may be play an important role in drug
resistance of tumor cells. In next work, we will investi-
gate the mechanisms that GADD45a decreases che-
motherapeutic sensitivity to DDP.
In summary, overexpression and promoter hypo-
methylation of GADD45a gene and global DNA hypo-
methylation were found in ESCC tissues, which provide
evidence that promoter hypomethylation may be the
major mechanism for activating GADD45a gene in
ESCC. The function of GADD45a in cell proliferation
and apoptosis further demonstrated that overexpression
of GADD45a contributes to the development of ESCC.
However, the experiment of drug sensitivity indicated
that GADD45a may be a protecting factor in DDP
chemotherapy.
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